Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

NCT00100347 is registered in ClinicalTrials.gov with PRAECIS Pharmaceuticals Inc. as lead sponsor.

NCT NCT00100347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00100347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2004
Completion date
July 31, 2007
Enrollment
45 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma,, solid tumors